AI MARKET SCANNING

Amylyx Pharmaceuticals, Inc.

📅 Next Catalyst: Nov 05, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Drug Manufacturers – Specialty & Generic
AVG HISTORICAL GAP -0.27%
MAX GAP RECORD -29.67%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $AMLX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
-3.43%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
-0.50%
Mar 03, 2026 Earnings Release 2026-03-03 (BEFORE OPEN)
+0.78%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
-1.96%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-2.32%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+9.68%
Mar 04, 2025 Earnings Release 2025-03-04 (BEFORE OPEN)
-6.67%

VOLATILITY & GAP BIAS

AVG GAP MOVE 6.3%
Bullish Gaps (5)
Bearish Gaps (6)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $AMLX

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 971m +0.00%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗